DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular ...

Dr. Tory Prestera and Dr. Howard Guan share key differences between dry and wet macular degeneration, including common symptoms, causes, and treatment options. Dry macular degeneration is the more ...

A local retinal surgeon and ophthalmology professor will speak about age-related macular degeneration during a free webinar ...

Two complement inhibitors tied to increased risk of wet AMD, but data called suspect ...

"The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President, CEO & Director Jay ...

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

But when the retina is damaged, vision can slowly become blurred, distorted or permanently lost, often before a person even ...

Ocular Therapeutix (NASDAQ:OCUL) management used its first-quarter 2026 earnings call to highlight clinical and regulatory ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...